On Tuesday, Medipost, the world’s leading stem cell biotech company, announced that its umbilical cord-derived allogeneic mesenchymal stem cell therapy, Cartistem, has achieved a milestone of 3,000 procedures for autologous cartilage restoration surgery at a single medical institution in South Korea.
This landmark achievement was reached at Gangnam JS Hospital in Seoul’s Gangnam district. It underscores Cartistem-based cartilage regeneration therapy’s long-term safety and efficacy in clinical practice, solidifying its position as a crucial alternative for knee joint cartilage regeneration.
The autologous cartilage restoration surgery using Cartistem applies umbilical cord-derived stem cell therapy to regenerate damaged knee joint cartilage.
This treatment aims to restore cartilage function and preserve the joint before resorting to artificial joint replacement, offering a new therapeutic paradigm for patients with degenerative knee osteoarthritis.
Since Cartistem’s introduction, Medipost has consistently validated the clinical efficacy and reproducibility of cartilage regeneration therapy through extensive clinical experience and collaboration with healthcare professionals.
A Medipost spokesperson stated that reaching 3,000 procedures at a single institution is a significant milestone. It demonstrates the long-term accumulation of Cartistem’s therapeutic effects and safety through ongoing collaboration with medical staff in clinical settings.